Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: A phase 3 randomized trial

被引：0
|
作者：
Bissonnette, R. [1 ]
Iversen, L. [2 ]
Sofen, H. [3 ]
Griffiths, C. E. M. [4 ,5 ]
Foley, P. [6 ]
Romiti, R. [7 ]
Bachinsky, M. [8 ]
Rottinghaus, S. T. [8 ]
Tan, H. [8 ]
Proulx, J. [8 ]
Valdez, H. [9 ]
Gupta, P. [8 ]
Mallbris, L. [10 ]
Wolk, R. [8 ]
机构：
[1] Innovaderm Res, Montreal, PQ, Canada
[2] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark
[3] Univ Calif Los Angeles, Sch Med, Dept Med Dermatol, Los Angeles, CA USA
[4] Univ Manchester, Dermatol Ctr, Manchester, Lancs, England
[5] Manchester Acad Hlth Sci Ctr, Manchester, Lancs, England
[6] Univ Melbourne, Skin & Canc Fdn Inc, Carlton, Vic 3053, Australia
[7] Univ Sao Paulo, Fac Med, Hosp Clin, Sao Paulo, Brazil
[8] Pfizer Inc, Groton, CT 06340 USA
[9] Pfizer Inc, New York, NY USA
[10] Pfizer Inc, Collegeville, PA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：37 / 37
页数：1
相关论文
共 50 条
  • [41] Safety of tildrakizumab for moderate-to-severe chronic plaque psoriasis: Pooled analysis of three randomized controlled studies
    Blauvelt, Andrew
    Reich, Kristian
    Papp, Kim A.
    Kimball, Alexa B.
    Gooderham, Melinda
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Li, Qing
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB252 - AB252
  • [42] Maintenance of Efficacy Results from UNCOVER-1: A Phase 3 Trial of Ixekizumab for Moderate-to-Severe Plaque Psoriasis
    Leonardi, C.
    Leutz, A.
    Blauvelt, A.
    Langley, R. G.
    Luger, T.
    Ohtsuki, M.
    Cameron, G. S.
    Erickson, J.
    Zhao, F.
    Shrom, D. S.
    Braun, D.
    Osuntokun, O. O.
    Heffernan, M.
    Nickoloff, B. J.
    Gordon, K.
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2016, 14 : 4 - 4
  • [43] Tofacitinib exposure-response characteristics in patients with moderate to severe chronic plaque psoriasis
    Gupta, Pankaj
    Hutmacher, Matthew
    Papp, Kim
    Lebwohl, Mark
    Ito, Kaori
    Tan, Huaming
    Wolk, Robert
    Mebus, Charles
    Rottinghausi, Scott T.
    Valdez, Hernan
    Mallbris, Lotus
    Krishnaswami, Sriram
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S8 - S8
  • [44] Maintenance of efficacy results from UNCOVER-1: A phase 3 trial of ixekizumab for moderate-to-severe plaque psoriasis
    Leonardi, Craig
    Blauvelt, Andrew
    Langley, Richard
    Luger, Thomas
    Ohtsuki, Mamitaro
    Cameron, Gregory S.
    Braun, Daniel
    Erickson, Janelle
    Zhao, Fangyi
    Shrorn, David S.
    Osuntokun, Olawale O.
    Heffernan, Michael P.
    Nickoloff, Brian
    Gordon, Kenneth
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S16 - S16
  • [45] Upadacitinib treatment withdrawal and retreatment in patients with moderate-to-severe atopic dermatitis: Results from a phase 2b, randomized, controlled trial
    Guttman-Yassky, Emma
    Silverberg, Jonathan I.
    Thaci, Diamant
    Papp, Kim A.
    Staender, Sonja
    Beck, Lisa A.
    Kim, Brian S.
    Hu, Xiaofei
    Liu, Jianzhong
    Calimlim, Brian M.
    Vigna, Namita
    Crowley, Jameson T.
    Teixeira, Henrique D.
    Thyssen, Jacob P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, 37 (12) : 2558 - 2568
  • [46] Effect of tofacitinib withdrawal and re-treatment on patient-reported outcomes: results from a Phase 3 study in patients with moderate to severe chronic plaque psoriasis
    Griffiths, C. E. M.
    Vender, R.
    Sofen, H.
    Kircik, L.
    Tan, H.
    Rottinghaus, S. T.
    Bachinsky, M.
    Mallbris, L.
    Mamolo, C.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2017, 31 (02) : 323 - 332
  • [47] Baseline cardiometabolic abnormalities in subjects with moderate-to-severe plaque psoriasis in the PRISTINE trial
    Puig, Lluis
    Strohal, Robert
    Estojak, Joanne
    Pedersen, Ronald
    Szumski, Annette
    Robertson, Deborah
    Freundlich, Bruce
    Molta, Charles
    Melin, Jeffrey
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2010, 130 : S68 - S68
  • [48] EfalizumabA Review of its Use in the Management of Chronic Moderate-to-Severe Plaque Psoriasis
    James E. Frampton
    Greg L. Plosker
    American Journal of Clinical Dermatology, 2009, 10 : 51 - 72
  • [49] Effect of tildrakizumab on personal relationships in patients with moderate-to-severe chronic plaque psoriasis
    Papp, Kim A.
    Kimball, Alexa B.
    Blauvelt, Andrew
    Reich, Kristian
    Gooderham, Melinda
    Tyring, Stephen K.
    Sinclair, Rodney
    Thaci, Diamant
    Zhou, Yang
    la Rosa, Carmen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB116 - AB116
  • [50] EFFECT OF TILDRAKIZUMAB ON PERSONAL RELATIONSHIPS IN PATIENTS WITH MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS
    Papp, Kim
    Kimball, Alexa
    Blauvelt, Andrew
    Reich, Kristian
    Gooderham, Melinda
    Tyring, Stephen
    Sinclair, Rodney
    Thaci, Diamant
    Zhao, Yang
    Cichanowitz, Nicole
    Li, Qing
    La Rosa, Carmen
    ACTA DERMATO-VENEREOLOGICA, 2018, 98 : 54 - 54
12345